Liquidia (NASDAQ:LQDA) Receives Buy Rating from Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Liquidia (NASDAQ:LQDA - Free Report) in a research note issued to investors on Thursday,Benzinga reports. They currently have a $19.00 target price on the stock.

Several other research analysts have also recently issued reports on the company. Scotiabank initiated coverage on Liquidia in a report on Wednesday, October 16th. They issued a "sector outperform" rating and a $30.00 price target on the stock. Lifesci Capital initiated coverage on shares of Liquidia in a research report on Thursday, October 3rd. They set an "outperform" rating and a $30.00 price objective on the stock. Raymond James upgraded shares of Liquidia from an "outperform" rating to a "strong-buy" rating in a research report on Monday, August 19th. Bank of America lowered their price objective on shares of Liquidia from $24.00 to $23.00 and set a "buy" rating on the stock in a research report on Tuesday, August 20th. Finally, BTIG Research lowered their price objective on shares of Liquidia from $29.00 to $25.00 and set a "buy" rating on the stock in a research report on Monday, August 19th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $24.00.

Liquidia Trading Down 2.4 %

NASDAQ:LQDA traded down $0.25 during midday trading on Thursday, hitting $10.02. 1,171,270 shares of the stock were exchanged, compared to its average volume of 981,237. Liquidia has a one year low of $6.10 and a one year high of $16.99. The company has a market capitalization of $769.48 million, a price-to-earnings ratio of -6.38 and a beta of 0.21. The business has a 50-day moving average price of $10.48 and a two-hundred day moving average price of $11.52.

Insider Buying and Selling

In related news, insider Rajeev Saggar sold 2,260 shares of the company's stock in a transaction on Monday, October 14th. The shares were sold at an average price of $11.11, for a total value of $25,108.60. Following the completion of the sale, the insider now directly owns 207,383 shares in the company, valued at approximately $2,304,025.13. This represents a 1.08 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other Liquidia news, insider Rajeev Saggar sold 2,260 shares of the business's stock in a transaction on Monday, October 14th. The shares were sold at an average price of $11.11, for a total transaction of $25,108.60. Following the completion of the transaction, the insider now owns 207,383 shares of the company's stock, valued at $2,304,025.13. The trade was a 1.08 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Michael Kaseta sold 3,892 shares of the business's stock in a transaction on Monday, October 14th. The stock was sold at an average price of $11.11, for a total transaction of $43,240.12. Following the transaction, the chief financial officer now directly owns 311,076 shares of the company's stock, valued at approximately $3,456,054.36. This represents a 1.24 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 21,551 shares of company stock worth $236,021. Corporate insiders own 30.10% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of LQDA. Swiss National Bank acquired a new position in Liquidia during the 1st quarter worth $1,325,000. Sei Investments Co. acquired a new position in shares of Liquidia during the first quarter valued at about $531,000. Bleakley Financial Group LLC raised its position in shares of Liquidia by 6.6% during the first quarter. Bleakley Financial Group LLC now owns 33,250 shares of the company's stock valued at $490,000 after buying an additional 2,057 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Liquidia by 1.5% during the first quarter. Vanguard Group Inc. now owns 2,887,274 shares of the company's stock valued at $42,587,000 after buying an additional 43,352 shares during the last quarter. Finally, American International Group Inc. raised its position in shares of Liquidia by 5.2% during the first quarter. American International Group Inc. now owns 24,806 shares of the company's stock valued at $366,000 after buying an additional 1,215 shares during the last quarter. Institutional investors and hedge funds own 64.54% of the company's stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).